Q4 2023 13F Holders as of 31 Dec 2023
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
294,683,714
-
Total 13F shares
-
75,056
-
Share change
-
-35,395
-
Total reported value
-
$42,895
-
Price per share
-
$0.57
-
Number of holders
-
2
-
Value change
-
-$20,037
-
Number of sells
-
2
Institutional Holders of SANGAMO THERAPEUTICS, INC - Common Stock (SGMO) as of Q4 2023
As of 31 Dec 2023,
SANGAMO THERAPEUTICS, INC - Common Stock (SGMO) was held by
2 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
75,056 shares.
The largest 10 holders included
BlackRock Inc., VANGUARD GROUP INC, WASATCH ADVISORS LP, ACADIAN ASSET MANAGEMENT LLC, D. E. Shaw & Co., Inc., GEODE CAPITAL MANAGEMENT, LLC, RENAISSANCE TECHNOLOGIES LLC, STATE STREET CORP, Hudson Bay Capital Management LP, and TWO SIGMA INVESTMENTS, LP.
This page lists
128
institutional shareholders reporting positions in this security
for the Q4 2023 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.